Compare Kohl's Corporation (KSS) vs Merck & Co., Inc. (MRK) Price & Performance

Kohl's CorporationTrade

Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Kohl's Corporation vs Merck & Co., Inc. — how do they compare? Kohl's Corporation trades at $19.24 (market cap $2.10B), while Merck & Co., Inc. trades at $133.12 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 153.2× Kohl's Corporation's market cap, and Kohl's Corporation pays the higher dividend (2.7%). Which is the better fit depends on your goals.

	KSS	MRK
Market Cap	$2.10B	$321.77B
Sector	Consumer Cyclical	Health
52-Week High	$24.71	$131.84
52-Week Low	$11.72	$77.60
Enterprise Value	$8.20B	$368.53B
Dividend Yield	2.7%	2.61%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kohl's Corporation

No Aura AI signal available yet.

Merck & Co., Inc.

MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.

MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

KSS

View details →

MRK

Merck reports 5% revenue growth in Q2 2026, boosted by KEYTRUDA and pipeline drugs, with positive analyst outlook.Danny Green · 10 hours agoBullish Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest.24/7 Wall Street · 13 hours agoBullish Bio-Techne reports flat FY2026 revenue, EPS rise, and confirms $11.3B acquisition by Merck KGaA.PRNewsWire · 15 hours agoBullish View details →

About Kohl's Corporation

Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.